Author(s):
Saravanan. R, Somanathan. T, Gavaskar. D, Sriraman. V, Tamilvanan. M, Sasieekhumar. A. R
Email(s):
soma.sbs@velsuniv.ac.in , soma_nano@yahoo.co.in
DOI:
10.52711/0974-360X.2022.00356 
Address:
Saravanan. R1, Somanathan. T1*, Gavaskar. D1, Sriraman. V1, Tamilvanan. M2, Sasieekhumar. A. R2
1Department of Chemistry, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, India.
2Department of Chemistry, VMKV Engineering College, Vinayaka Mission’s Research Foundation, Salem, Tamilnadu, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 5,
Year - 2022
ABSTRACT:
A novel, accurate, specific, linear, precise and robust RP-HPLC method (stability indicating) has been developed and validated for the related substances (impurities) analysis of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate in tablet formulation. This research paper presents the developed method and the outcome of validation challenges. The RP-HPLC method was developed on a 250 x 4.6 mm, 5 µm, C18 column, with a gradient mode using combination of phosphate buffer and phosphoric acid in methanol and water as mobile phase, the detection was performed at 265nm and 235nm. The method was subjected to validation challenges of specificity, precision, linearity, accuracy, robustness and is demonstrated to be suitable for testing of stability samples.
Cite this article:
Saravanan. R, Somanathan. T, Gavaskar. D, Sriraman. V, Tamilvanan. M, Sasieekhumar. A. R. Development and Validation of Stability Indicating Related Substances Method for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate (DLT) Tablets using High Performance Liquid Chromatography. Research Journal of Pharmacy and Technology. 2022; 15(5):2147-0. doi: 10.52711/0974-360X.2022.00356
Cite(Electronic):
Saravanan. R, Somanathan. T, Gavaskar. D, Sriraman. V, Tamilvanan. M, Sasieekhumar. A. R. Development and Validation of Stability Indicating Related Substances Method for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate (DLT) Tablets using High Performance Liquid Chromatography. Research Journal of Pharmacy and Technology. 2022; 15(5):2147-0. doi: 10.52711/0974-360X.2022.00356 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-5-38
REFERENCES:
1. Mechanisms of action, pharmacology and interactions of dolutegravir. Esteban Ribera and Daniel Podzamczer. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8.
2. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, Single Investigators. N Engl J Med. 2013 Nov 7; 369(19):1807-18.
3. Dolutegravir-A review of the pharmacology, efficacy, and safety in the treatment of HIV. Christopher E Kandel, Sharon L Walmsley. Drug Design, Development and Therapy 2015:9 3547-3555.
4. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. J Acquir Immune Defic Syndr. 2014 Aug 1; 66(4):393-8.
5. Drugs for HIV Infection. Benjamin J. Eckhardt, Roy M. Gulick, in Infectious Diseases (Fourth Edition), 2017
6. Laboratory Diagnosis and Therapy of Infectious Diseases. David W. Kimberlin, Principles and Practice of Pediatric Infectious Diseases (Fourth Edition), 2012
7. Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus. William E. Delaney, IV, Adrian S. Ray, Huiling Yang, Xiaoping Qi, Shelly Xiong, Yuao Zhu, and Michael D. Miller. Antimicrob Agents Chemother. 2006 Jul;50(7):2471-7.
8. https://database.ich.org/sites/default/files/Q2_R1__Guideline.pdf